Pharmaceutical Investing Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder
Pharmaceutical Investing Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU
Pharmaceutical Investing Positive Regulatory News from Two Pharmaceutical Companies Triggers Share Price Increases
